Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke

被引:55
作者
Aznar, J
Mira, Y
Vayá, A
Corella, D
Ferrando, F
Villa, P
Estellés, A
机构
[1] La Fe Univ Hosp, Dept Clin Pathol, Valencia 46009, Spain
[2] La Fe Univ Hosp, Res Ctr, Valencia, Spain
[3] Univ Valencia, Sch Med, Mol Epidemiol Unit, Valencia, Spain
关键词
stroke; factorV Leiden; prothrombin G20210A mutation; cryptogenic stroke; oral contraceptives;
D O I
10.1160/TH03-11-0690
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The association between factor V Leiden (FVL) and prothrombin G20210A (PT 20210) mutations and ischemic stroke remains controversial, particularly in young adults with cryptogenic stroke. Prevalence of FVL (4.1%) and PT 20210 (8.2%) mutations was assessed in 49 patients under 50 years with cryptogenic stroke and compared with controls. Odd ratio (OR) for cryptogenic stroke was 2.62 (95% CI, 0.49-13.95) for FVL and 3.75 (95% CI, 1.05-13.34) for PT 20210 and 3.28 (95% CI, 1,17-9.20) for some recognized genetic thrombophilic defect. Moreover, the OR for cryptogenic stroke in young women using oral contraceptives (OC) was 3.59 (95% CI, 1.28-10.5). When some genetic thrombophilic defect was associated with OC, the OR was much higher (OR: 14.27; 95% CI, 0.66-309.99). Our results suggest that in the Mediterranean populations the PT 20210 mutation, but not FV Leiden, is a risk factor for cryptogenic stroke in young adults. OC use is also a significant risk factor for cryptogenic stroke, which is increased in women with some genetic thrombotic risk factor.
引用
收藏
页码:1031 / 1034
页数:4
相关论文
共 38 条
[1]  
Albucher JF, 1996, STROKE, V27, P766
[2]   Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women [J].
Austin, H ;
Chimowitz, M ;
Hill, HA ;
Chaturvedi, S ;
Wechsler, LR ;
Wityk, RJ ;
Walz, E ;
Wilterdink, JL ;
Coull, B ;
Sila, CA ;
Mitsias, P ;
Evatt, B ;
Hooper, WC ;
Genetics Stroke Young Study Grp .
STROKE, 2002, 33 (12) :2762-2768
[3]  
Aznar J, 2000, HAEMATOLOGICA, V85, P1271
[4]  
Bentolila S, 1997, STROKE, V28, P1846
[5]   Diagnostic testing for coagulopathies in patients with ischemic stroke [J].
Bushnell, CD ;
Goldstein, LB .
STROKE, 2000, 31 (12) :3067-3078
[6]   FACTOR-V LEIDEN GENE MUTATION AND THROMBIN GENERATION IN RELATION TO THE DEVELOPMENT OF ACUTE STROKE [J].
CATTO, A ;
CARTER, A ;
IRELAND, H ;
BAYSTON, TA ;
PHILIPPOU, H ;
BARRETT, J ;
LANE, DA ;
GRANT, PJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (06) :783-785
[7]  
Cushman M, 1998, THROMB HAEMOSTASIS, V79, P912
[8]   Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients [J].
De Stefano, V ;
Chiusolo, P ;
Paciaroni, K ;
Casorelli, I ;
Rossi, E ;
Molinari, F ;
Servidei, S ;
Tonali, PA ;
Leone, G .
BLOOD, 1998, 91 (10) :3562-3565
[9]   A RAPID SCREENING METHOD FOR THE FACTOR-V ARG506-]GLN MUTATION [J].
GANDRILLE, S ;
ALHENCGELAS, M ;
AIACH, M .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (03) :245-248
[10]   Activated protein C resistance in childhood stroke [J].
Ganesan, V ;
Kelsey, H ;
Cookson, J ;
Osborn, A ;
Kirkham, FJ .
LANCET, 1996, 347 (8996) :260-260